<DOC>
	<DOCNO>NCT01655069</DOCNO>
	<brief_summary>This 40-week study investigate safe effective solifenacin solution treat children/adolescents symptom overactive bladder ( OAB ) complete study 905-CL-076 . To measure efficacy treatment patient complete 7-day patient diary prior every visit , start Visit 9 . The patient attend study clinic 7 separate occasion . The first visit study ( 905-CL-077 ) combine last visit 4-month study 905-CL-076 . At visit , patient require undertake number assessment examination determine whether safe him/her take part continue take part study . During first 3 visit dosage study drug adjust need order optimize effective safe dose patient .</brief_summary>
	<brief_title>A Study Investigate How Safe Effective Solifenacin Solution Treating Children/Adolescents With Symptoms Overactive Bladder ( OAB ) Who Completed Study 905-CL-076</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Subject meet inclusion criterion study 905CL076 complete study 905CL076 Subject fail exclusion criterion study 905CL076</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Overactive bladder ( OAB )</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Solifenacin succinate suspension</keyword>
	<keyword>Phase 3</keyword>
</DOC>